Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

December 2022 News Roundup

News Opinion CV Team Dispatch

December 2022 News Roundup

December 28, 2022

Amulet, Watchman 2.5 LAAO Devices Provide Comparable 3-Year Outcomes

News Conference News TCT 2022

Amulet, Watchman 2.5 LAAO Devices Provide Comparable 3-Year Outcomes

September 18, 2022

Late Bleeding Not Rare, Ups Mortality After TAVI in All-Asian Cohort: OCEAN-TAVI

News Daily News

Late Bleeding Not Rare, Ups Mortality After TAVI in All-Asian Cohort: OCEAN-TAVI

Yael L. Maxwell

September 08, 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

News Conference News ESC 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

Michael O'Riordan

September 07, 2022

Watchman FLX Gets DAPT Option Added to Label

News Daily News

Watchman FLX Gets DAPT Option Added to Label

September 06, 2022

Peridevice Leaks After LAA Occlusion Signal Poorer 5-Year Outcomes

News Daily News

Peridevice Leaks After LAA Occlusion Signal Poorer 5-Year Outcomes

July 28, 2022

More Support for Single Antiplatelet Therapy After TAVI

News Conference News TVT 2022

More Support for Single Antiplatelet Therapy After TAVI

Michael O'Riordan

June 10, 2022

LAA Occlusion With Watchman Provides Good Early Results in China

News Daily News

LAA Occlusion With Watchman Provides Good Early Results in China

June 07, 2022

NCDR Analyses Offer Insights Into First-Generation Watchman Outcomes

News Daily News

NCDR Analyses Offer Insights Into First-Generation Watchman Outcomes

May 03, 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

News Conference News ACC 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

April 05, 2022

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

Presentation ACC 2022

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

Presenter: Duk-Woo Park

April 04, 2022

March 2022 News Roundup

News Opinion CV Team Dispatch

March 2022 News Roundup

March 01, 2022

February 2022 News Roundup

News Opinion CV Team Dispatch

February 2022 News Roundup

February 01, 2022

January 2022 News Roundup

News Opinion CV Team Dispatch

January 2022 News Roundup

January 01, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.